Highlights

  • Healius shares traded at AUD 0.38, up 2.67%, at the time of writing on 3 August 2026.
  • FY26 results are scheduled for 19 August 2026, providing the next major catalyst.
  • The company has strengthened its Balance Sheet following the Lumus Imaging divestment.
  • Investors remain focused on pathology margins, Agilex Biolabs and FY26 Earnings guidance.

Healius (ASX:HLS) has spent the past two years reshaping its Business through asset sales, Debt reduction and operational restructuring. As the company approaches the release of its FY26 results on 19 August 2026, investors are assessing whether these initiatives are beginning to translate into a more sustainable earnings recovery. The latest improvement in the share price reflects renewed market interest, but the upcoming results are expected to provide the clearest indication yet of the company's progress.

Share price in focus

Healius shares traded at AUD 0.38, up 2.67%, at the time of writing on 3 August 2026.

The modest gain comes as investors position ahead of the company's FY26 financial results. While short-term share-price movements often reflect broader market sentiment, the upcoming Earnings Announcement is expected to provide greater clarity on operational performance and management's outlook.

Company transformation continues

Few ASX-listed healthcare companies have undergone as much structural change as Healius in recent years.

Previously operating across pathology, diagnostic imaging and medical centres, the company has progressively streamlined its business to focus primarily on pathology services and its Clinical Trials business, Agilex Biolabs.

A defining milestone in that transformation came with the completion of the A$965 million sale of Lumus Imaging in May 2025.

Management used the proceeds to:

  • Repay approximately A$515 million of debt.
  • Refinance remaining borrowings through a new A$300 million Facility .
  • Return approximately A$299.9 million to shareholders through a Special Dividend of 41.3 cents per share.

The transaction fundamentally changed Healius' financial profile, reducing Leverage while simplifying the business around its core pathology operations.

Why the FY26 results matter

The FY26 results, scheduled for 19 August 2026, represent an important milestone in the company's turnaround strategy.

Following the Lumus sale, Healius has become largely a pure-play pathology provider, supported by the faster-growing Agilex Biolabs business.

This creates both opportunities and challenges.

On one hand, management can focus resources on improving operational efficiency within pathology while expanding higher-growth businesses such as genomics, veterinary pathology and clinical trials.

On the other, pathology remains a mature industry characterised by regulated pricing, labour-intensive operations and ongoing cost pressures.

The upcoming results will therefore be closely watched for evidence that operational improvements are translating into stronger profitability.

Financial performance

The first half of FY26 demonstrated encouraging progress across several financial metrics.

For the six months ended 31 December 2025, Healius reported:

  • Revenue increased 3.8% to A$688.1 million.
  • Underlying EBITDA rose 13.1% to A$122.2 million.
  • Underlying EBIT improved to a A$7.9 million profit, compared with a A$2.7 million loss in the prior corresponding period.

Within the company's operating segments:

  • Pathology revenue (excluding Agilex) increased 3.5% to A$666.3 million.
  • Agilex Biolabs revenue increased 16% to A$21.8 million.
  • Agilex EBIT surged 145.5% to A$2.7 million.

The statutory result remained negative, however, with the company reporting a A$30.4 million net loss for the half.

Despite this, the improvement in underlying earnings suggested that cost reduction initiatives and operational efficiencies were beginning to gain traction.

A much stronger balance sheet

One of the most significant improvements has been Healius' financial position.

At 31 December 2025, the company reported:

  • Cash of A$51.6 million.
  • Drawn debt of A$40 million.
  • Net cash of A$11.6 million.

This represents a substantial turnaround compared with previous years when elevated debt levels weighed heavily on investor sentiment.

The stronger balance sheet provides management with greater financial flexibility while reducing refinancing risk.

For FY26, management has guided to:

  • Underlying EBITDA of A$259–264 million.
  • Underlying EBIT of A$30–35 million.

Meeting or exceeding this guidance will likely be a key determinant of investor confidence following the August results.

Agilex strategic review

Another important development is the strategic review of Agilex Biolabs.

The company appointed UBS to evaluate strategic Options after receiving unsolicited interest in the business.

Agilex has become one of Healius' fastest-growing operations, supported by increasing Demand for clinical trial services.

Any outcome from the review could reshape the company's future Capital allocation strategy while potentially unlocking additional Shareholder value.

However, no decision has yet been announced, and investors will likely seek further updates alongside the FY26 results.

Growth opportunities

Management continues identifying opportunities to strengthen earnings across several areas.

These include:

  • Improving pathology operating margins.
  • Expanding genomics services.
  • Growing veterinary pathology.
  • Continuing Agilex expansion.
  • Delivering operational efficiency initiatives.
  • Progressing toward the company's medium-term Margin targets.

Management has also outlined an objective of achieving high single-digit EBIT margins by June 2027, reflecting its longer-term operational ambitions.

If successfully delivered, these initiatives could support improved profitability over the coming years.

Risks and uncertainties

Despite recent progress, several challenges remain.

Pathology continues to operate in a tightly regulated environment where Medicare reimbursement growth remains limited.

Labour costs also remain a significant issue.

The Fair Work Commission's decision regarding gender-based undervaluation is expected to increase pathology labour expenses, with the company estimating an additional A$1.8 million impact during the final quarter of FY26, followed by further phased increases over coming years.

The company also continues reporting statutory losses despite improving underlying earnings, highlighting that the turnaround remains incomplete.

Operational performance, pathology volumes and ongoing cost management will therefore remain critical.

What investors should watch

The FY26 results on 19 August 2026 are expected to be the next major catalyst.

Investors are likely to focus on:

  • Delivery against FY26 EBITDA and EBIT guidance.
  • Pathology margin improvement.
  • Progress toward June 2027 margin targets.
  • Updates on the Agilex strategic review.
  • Pathology Volume trends.
  • Labour cost management.
  • Capital allocation priorities and dividend policy.

Management commentary regarding FY27 trading conditions will also be closely monitored.

The Bottom Line

Healius has made meaningful progress in strengthening its balance sheet and simplifying its business following the sale of Lumus Imaging.

The company has reduced debt, returned capital to shareholders and reported improving underlying earnings, while Agilex continues delivering encouraging growth.

However, the turnaround remains a work in progress. Statutory profitability has yet to return, labour costs continue rising and pathology remains a competitive, tightly regulated industry.

The FY26 results on 19 August 2026 are expected to provide the clearest indication yet of whether Healius is moving beyond stabilisation and toward a more sustainable recovery.